NEW YORK (GenomeWeb News) – Bruker today reported that revenues for its second quarter increased 5 percent year over year as the company missed the consensus Wall Street estimate on the top and bottom line.

For the three months ended June 30, Bruker posted revenues of $420.7 million, up from the year-ago figure of $401.2 million, but short of the average analyst estimate of $425 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.